In this post hoc analysis of the SURPASS-CVOT randomized trial involving 13,165 patients with type 2 diabetes and established cardiovascular disease, tirzepatide was associated with a significantly lower risk of a composite cardiorenal outcome—including all-cause mortality, myocardial infarction, stroke, coronary revascularization, heart failure hospitalization, and adverse kidney events—compared with dulaglutide. These findings suggest that dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonism may provide broader cardiometabolic and renal risk reduction than glucagon-like peptide-1 receptor agonist therapy alone in high-risk patients, with a safety profile primarily notable for increased gastrointestinal adverse events.

Source: JAMA Cardiology